Publication: Dengue: A continuing global threat
| dc.contributor.author | Maria G. Guzman | en_US |
| dc.contributor.author | Scott B. Halstead | en_US |
| dc.contributor.author | Harvey Artsob | en_US |
| dc.contributor.author | Philippe Buchy | en_US |
| dc.contributor.author | Jeremy Farrar | en_US |
| dc.contributor.author | Duane J. Gubler | en_US |
| dc.contributor.author | Elizabeth Hunsperger | en_US |
| dc.contributor.author | Axel Kroeger | en_US |
| dc.contributor.author | Harold S. Margolis | en_US |
| dc.contributor.author | Eric Martí-nez | en_US |
| dc.contributor.author | Michael B. Nathan | en_US |
| dc.contributor.author | Jose Luis Pelegrino | en_US |
| dc.contributor.author | Cameron Simmons | en_US |
| dc.contributor.author | Sutee Yoksan | en_US |
| dc.contributor.author | Rosanna W. Peeling | en_US |
| dc.contributor.other | Instituto de Medicina Tropical Pedro Kouri | en_US |
| dc.contributor.other | Pediatric Dengue Vaccine Initiative | en_US |
| dc.contributor.other | National Microbiology Laboratory | en_US |
| dc.contributor.other | Institut Pasteur du Cambodge | en_US |
| dc.contributor.other | UCL | en_US |
| dc.contributor.other | Duke-NUS Graduate Medical School Singapore | en_US |
| dc.contributor.other | Centers for Disease Control and Prevention San Juan | en_US |
| dc.contributor.other | Organisation Mondiale de la Sante | en_US |
| dc.contributor.other | Mahidol University | en_US |
| dc.contributor.other | London School of Hygiene & Tropical Medicine | en_US |
| dc.date.accessioned | 2018-09-24T09:09:05Z | |
| dc.date.available | 2018-09-24T09:09:05Z | |
| dc.date.issued | 2010-01-01 | en_US |
| dc.description.abstract | Dengue fever and dengue haemorrhagic fever are important arthropod-borne viral diseases. Each year, there are ~50 million dengue infections and ~500,000 individuals are hospitalized with dengue haemorrhagic fever, mainly in Southeast Asia, the Pacific and the Americas. Illness is produced by any of the four dengue virus serotypes. A global strategy aimed at increasing the capacity for surveillance and outbreak response, changing behaviours and reducing the disease burden using integrated vector management in conjunction with early and accurate diagnosis has been advocated. Antiviral drugs and vaccines that are currently under development could also make an important contribution to dengue control in the future. © 2010 Macmillan Publishers Limited. All rights reserved. | en_US |
| dc.identifier.citation | Nature Reviews Microbiology. Vol.8, No.12 (2010), S7-S16 | en_US |
| dc.identifier.doi | 10.1038/nrmicro2460 | en_US |
| dc.identifier.issn | 17401534 | en_US |
| dc.identifier.issn | 17401526 | en_US |
| dc.identifier.other | 2-s2.0-79955602230 | en_US |
| dc.identifier.uri | https://repository.li.mahidol.ac.th/handle/123456789/29292 | |
| dc.rights | Mahidol University | en_US |
| dc.rights.holder | SCOPUS | en_US |
| dc.source.uri | https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=79955602230&origin=inward | en_US |
| dc.subject | Immunology and Microbiology | en_US |
| dc.title | Dengue: A continuing global threat | en_US |
| dc.type | Article | en_US |
| dspace.entity.type | Publication | |
| mu.datasource.scopus | https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=79955602230&origin=inward | en_US |
